Neuropathology of parkinson's disease

Inflammation in Parkinson's Disease: Scientific and Clinical Aspects

Volumn , Issue , 2014, Pages 25-74

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930320378     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-08046-8_2     Document Type: Chapter

References (404)

1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011;26 Suppl 1:S1-58.
2. Bach JP, Ziegler U, Deuschl G, Dodel R, Doblhammer-Reiter G. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord. 2011;26:2286-90.
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839-40.
4. Jellinger KA. Lewy body disorders. In: Youdim MBH, Riederer P, Mandel SA, Battistin L, Lajtha A, editors. Degenerative diseases of the nervous system. New York: Springer Science; 2007. p. 267-343.
5. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119:689-702.
6. Braak H, Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70:1916-25.
7. Fumimura Y, Ikemura M, Saito Y, Sengoku R, Kanemaru K, Sawabe M, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neuropathol Exp Neurol. 2007;66:354-62.
8. Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, Kanemaru K, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol. 2008;67:945-53.
9. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, et al. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2013;72:119-29.
10. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain. 2008;131:642-50.
11. Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopa-thies of the brain. Acta Neuropathol. 2010;120:1-12.
12. Jellinger KA. The role of alpha-synuclein in neurodegeneration-an update. Transl Neurosci. 2012;3:75-122.
13. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord. 2012;27:8-30.
14. Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol. 2013;47: 495-508.
15. Halliday G, McCann H, Shepherd C. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Expert Rev Neurother. 2012;12:673-86.
16. DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol. 2008;65:1074-80.
17. Dickson DW, Fujishiro H, Delledonne A, Menke J, Ahmed Z, Klos KJ, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008;115:437-44.
18. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006;32:284-95.
19. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre-and postganglionic neurons. Acta Neuropathol. 2007;113:421-9.
20. Gold A, Turkalp ZT, Munoz DG. Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. Mov Disord. 2013;28:237-40.
21. Probst A, Bloch A, Tolnay M. New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur J Neurol. 2008;15 Suppl 1:1-4.
22. Lebouvier T, Chaumette T, Paillusson S, Duyckaerts C, Bruley des Varannes S, Neunlist M, et al. The second brain and Parkinson's disease. Eur J Neurosci. 2009;30:735-41.
23. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience. 2008;153:733-50.
24. Braak H, Del Tredici K, Rub U, de Vo s RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
25. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33:599-614.
26. Akhtar RS, Stern MB. New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications. Expert Rev Neurother. 2012;12:1429-38.
27. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464-74.
28. Lang AE. A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord. 2011;26: 775-83.
29. Massano J, Bhatia KP. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med. 2012;2:a008870.
30. Pfeiffer RF, Bodis-Wollner I, editors. Parkinson's disease and nonmotor dysfunction. New York: Springer Science + Business Media; 2013.
31. Tolosa E, Santamaria J, Gaig C, Compta Y. Nonmotor aspects of Parkinson's disease. In: Schapira AHV, Lang AET, Fahn S, editors. Movement disorders 4. Philadelphia: Saunders-Elsevier; 2010. p. 229-51.
32. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008; 23:837-44.
33. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol. 2002;249:138-45.
34. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology. 2009;73:206-12.
35. Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson's disease. Mov Disord. 2012;27:54-60.
36. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011;122:187-204.
37. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain. 2009;132:2947-57.
38. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of Parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861-70.
39. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055-66.
40. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467-86.
41. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, et al. Diagnostic criteria for the neuropathological assessment of Parkinson disease: Report of the Neuropathology and Genetics Working Group of the Second International Brainstorming Conference on Parkinson disease. Lancet Neurol. 2009;8:1150-7.
42. Dickson DW. Parkinson's disease and Parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2:a009258.
43. Halliday G, Lees A, Stern M. Milestones in Parkinson's disease-clinical and pathologic features. Mov Disord. 2011;26:1015-21.
44. Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov Disord. 2011;26:1042-8.
45. Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. Mov Disord. 2013;28:24-30.
46. Jellinger KA. Synuclein and Parkinson's disease: an update. In: Martinez A, Gil C, editors. Emerging drugs and targets for Parkinson's disease. London: The Royal Society of Chemistry; 2013. p. 175-214.
47. Duda JE, Dickson DW. Neuropathology of Parkinson's disease. In: Pfeiffer RF, Wszolek ZK, Ebadi M, editors. Parkinson's disease. 2nd ed. Boca Raton: CRC Press; 2013. p. 492-506.
48. Halliday G, Murphy K. Pathology of Parkinson's disease-an overview. In: Schapira AHV, Lang AET, Fahn S, editors. Movement disorders 4. Philadelphia: Saunders-Elsevier; 2010. p. 132-54.
49. Jellinger KA. Parkinson's disease. In: Dickson DW, Weller RO, editors. Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed. Oxford: Blackwell Publishing Ltd.; 2011. p. 194-223.
50. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 2012;124:325-38.
51. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord. 2012;27:831-42.
52. Muntane G, Dalfo E, Martinez A, Ferrer I. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience. 2008;152:913-23.
53. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010;120:131-43.
54. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122 (Pt 8):1437-48.
55. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318:876-80.
56. Rajput AH, Sitte HH, Rajput A, Fenton ME, PiflC, Hornykiewicz O. Globus pallidus dopa-mine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology. 2008;70:1403-10.
57. Porritt MJ, Kingsbury AE, Hughes AJ, Howells DW. Striatal dopaminergic neurons are lost with Parkinson's disease progression. Mov Disord. 2006;21:2208-11.
58. Tandé D, Hoglinger G, Debeir T, Freundlieb N, Hirsch EC, Francois C. New striatal dopa-mine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogen-esis. Brain. 2006;129:1194-200.
59. Mundinano IC, Caballero MC, Ordonez C, Hernandez M, DiCaudo C, Marcilla I, et al. Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. Acta Neuropathol. 2011;122:61-74.
60. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol. 2011;69:803-10.
61. Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, et al. Regional volume analysis of the Parkinson disease brain in early disease stage: gray matter, white matter, striatum, and thala-mus. AJNR Am J Neuroradiol. 2011;32:682-7.
62. Shih MC, Franco de Andrade LA, Amaro Jr E, Felicio AC, Ferraz HB, Wagner J, et al. Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?-a [99mTc]-TRODAT-1 SPECT study. Mov Disord. 2007;22:863-6.
63. Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci. 1997;151:83-7.
64. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminer-gic dysfunction in Parkinson's disease: a longitudinal (18)F-dopa PET study. Neuroimage. 2011;56:1463-8.
65. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemi-cal correlations. J Neurol Sci. 1973;20:415-55.
66. Ziegler DA, Wonderlick JS, Ashourian P, Hansen LA, Young JC, Murphy AJ, et al. Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol. 2013;70:241-7.
67. Rudow G, O'Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol. 2008;115:461-70.
68. Djaldetti R, Lorberboym M, Karmon Y, Treves TA, Ziv I, Melamed E. Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: a single photon emission computed tomography imaging study. Mov Disord. 2011;26:327-30.
69. Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Mov Disord. 2008;23:1608-12.
70. Chu Y, Morfini GA, Langhamer LB, He Y, Brady ST, Kordower JH. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012;135: 2058-73.
71. Ma SY, Ciliax BJ, Stebbins G, Jaffar S, Joyce JN, Cochran EJ, et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol. 1999;409:25-37.
72. Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol. 2002;28: 283-91.
73. Kingsbury AE, Marsden CD, Foster OJ. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study. Mov Disord. 1999;14:206-18.
74. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord. 2008;23: 474-83.
75. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132-44.
76. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotec-tion? Lancet Neurol. 2009;8:382-97.
77. Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol. 2009;89:277-87.
78. Pradhan S, Andreasson K. Commentary: progressive inflammation as a contributing factor to early development of Parkinson's disease. Exp Neurol. 2013;241:148-55.
79. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37:510-8.
80. Tufekci KU, Meuwissen R, Genc S, Genc K. Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol. 2012;88:69-132.
81. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res. 2011; 69:337-42.
82. Wakabayashi K, Mori F, Takahashi H. Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson's disease. Parkinsonism Relat Disord. 2006;12(suppl):S92-8.
83. Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging. 2008;31:99-103.
84. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neuro-biology of axons. Ann Neurol. 2010;67:715-25.
85. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136: 2419-31.
86. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol. 2009;201:1-119.
87. Zhou ZD, Lan YH, Tan EK, Lim TM. Iron species-mediated dopamine oxidation, protea-some inhibition, and dopaminergic cell demise: implications for iron-related dopaminergic neuron degeneration. Free Radic Biol Med. 2010;49:1856-71.
88. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC. Neuromelanin-associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem. 2003;86:1142-8.
89. Lv Z, Jiang H, Xu H, Song N, Xie J. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm. 2011;118: 361-9.
90. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol. 2010;84:825-89.
91. Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogen-esis of Parkinson's disease. J Neurochem. 2011;118:939-57.
92. Wypijewska A, Galazka-Friedman J, Bauminger ER, Wszolek ZK, Schweitzer KJ, Dickson DW, et al. Iron and reactive oxygen species activity in Parkinsonian substantia nigra. Parkinsonism Relat Disord. 2010;16:329-33.
93. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain. 2005;128:2654-64.
94. Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M. Alpha-Synuclein expression is modulated at the translational level by iron. Neuroreport. 2012;23:576-80.
95. Levin J, Högen T, Hillmer AS, Bader B, Schmidt F, Kamp F, et al. Generation of ferric iron links oxidative stress to alpha-synuclein oligomer formation. J Parkinsons Dis. 2011;1: 205-16.
96. Fasano M, Bergamasco B, Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem. 2006;96:909-16.
97. Guerrero E, Vasudevaraju P, Hegde ML, Britton GB, Rao KS. Recent advances in alpha-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease. Mol Neurobiol. 2013;47:525-36.
98. Ruiperez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res. 2010;49:420-8.
99. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol. 2000;166: 127-35.
100. Mogi M, Togari A, Kondo T, Mizuno Y, Kogure O, Kuno S, et al. Glial cell line-derived neurotrophic factor in the substantia nigra from control and Parkinsonian brains. Neurosci Lett. 2001;300:179-81.
101. Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat. 2001;21:277-88.
102. Knott C, Stern G, Kingsbury A, Welcher AA, Wilkin GP. Elevated glial brain-derived neuro-trophic factor in Parkinson's disease nigra. Parkinsonism Relat Disord. 2002;8:329-41.
103. Gu G, Reyes PE, Golden GT, Woltjer RL, Hulette C, Montine TJ, et al. Mitochondrial DNA deletions/rearrangements in Parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol. 2002;61:634-9.
104. Winslow AR, Rubinsztein DC. The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy. 2011;7:429-31.
105. Double KL, Reyes S, Werry EL, Halliday GM. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol. 2010;92:316-29.
106. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-301.
107. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol. 1997;144:202-13.
108. Matzuk MM, Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol. 1985;18:552-5.
109. Fronczek R, Overeem S, Lee S Y, Hegeman IM, van Pelt J, van Duinen SG, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain. 2007;130:1577-85.
110. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain. 2007;130:1586-95.
111. Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron. 2011;71:35-48.
112. Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65: 685-97.
113. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 1991;14:153-97.
114. Benarroch EE, Schmeichel AM, Low PA, Boeve BF, Sandroni P, Parisi JE. Involvement of medullary regions controlling sympathetic output in Lewy body disease. Brain. 2005;128: 338-44.
115. Benarroch EE, Schmeichel AM, Low PA, Parisi JE. Depletion of putative chemosensitive respiratory neurons in the ventral medullary surface in multiple system atrophy. Brain. 2007;130:469-75.
116. Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD. J Neurol Sci. 2010;289:81-8.
117. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S1-5.
118. Silveira-Moriyama L, Holton JL, Kingsbury A, Ayling H, Petrie A, Sterlacci W, et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett. 2009;453:77-80.
119. Tamura T, Yoshida M, Hashizume Y, Sobue G. Lewy body-related alpha-synucleinopathy in the spinal cord of cases with incidental Lewy body disease. Neuropathology. 2012;32: 13-22.
120. Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol. 2012;124:643-64.
121. Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson's disease. Mov Disord. 2009;24:793-800.
122. Duda JE. Olfactory system pathology as a model of Lewy neurodegenerative disease. J Neurol Sci. 2010;289:49-54.
123. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005;64:1404-10.
124. Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 2005;15:29-34.
125. Ghebremedhin E, Del Tredici K, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol. 2009;118:777-84.
126. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol. 2007;17:24-30.
127. Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, Kakita A, et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol. 2007; 113:81-6.
128. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain. 2009;132:1128-45.
129. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117:613-34.
130. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 2012;124:665-80.
131. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008;115:445-51.
132. Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, DelleDonne A, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging. 2011;32:857-63.
133. Doppler K, Ebert s, Üçeyler N, Trenkwalder C, Ebentheuer J, Volkmann J, et al. Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol 2014; 128:99-109.
134. Lema Tomé CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P. Inflammation and alpha-synuclein's prion-like behavior in Parkinson's disease-is there a link? Mol Neurobiol. 2013;47:561-74.
135. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, et al. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol. 2012;72:517-24.
136. Lue L-F, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, et al. Biochemical increase in phosphorylated a-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012;22:745-56.
137. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, Ortega-Moreno A, Rebollo AC, Gomez-Rio M, et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. Neurology. 2007;68:2012-8.
138. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol. 2008;64:485-91.
139. Kanazawa T, Adachi E, Orimo S, Nakamura A, Mizusawa H, Uchihara T. Pale neurites, premature alpha-synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol. 2012;22:67-78.
140. Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN. Relationships between Lewy bodies and pale bodies in Parkinson's disease. Acta Neuropathol. 1992;83:525-9.
141. Katsuse O, Iseki E, Marui W, Kosaka K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci. 2003;211:29-35.
142. Lundblad M, Decressac M, Mattsson B, Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA. 2012;109:3213-9.
143. Garcia-Reitböck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 2010;133:2032-44.
144. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci. 2009;12:826-8.
145. Stoica G, Lungu G, Bjorklund NL, Taglialatela G, Zhang X, Chiu V, et al. Potential role of alpha-synuclein in neurodegeneration: studies in a rat animal model. J Neurochem. 2012; 122:812-22.
146. Nakata Y, Yasuda T, Fukaya M, Yamamori S, Itakura M, Nihira T, et al. Accumulation of alpha-synuclein triggered by presynaptic dysfunction. J Neurosci 2012;32:17186-96.
147. Milber JM, Noorigian J V, Morley JF, Petrovitch H, White L, Ross GW, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology. 2012;79:2307-14.
148. Bellucci A, Zaltieri M, Navarria L, Grigoletto J, Missale C, Spano P. From alpha-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res. 2012;1476:183-202.
149. Mori F, Nishie M, Kakita A, Yoshimoto M, Takahashi H, Wakabayashi K. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J Neuropathol Exp Neurol. 2006;65:808-15.
150. Sidhu A, Wersinger C, Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J. 2004;18:637-47.
151. Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain. 2010;133:172-88.
152. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol. 2010;225:210-8.
153. Quinn JG, Coulson DT, Brockbank S, Beyer N, Ravid R, Hellemans J, et al. Alpha-synuclein mRNA and soluble alpha-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. Brain Res. 2012;1459:71-80.
154. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4:160-4.
155. Beyer K, Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol. 2013;47:509-24.
156. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol. 2003;62:1241-53.
157. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, et al. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type his-topathology in human brains. Exp Neurol 2013;240:190-204.
158. Wilhelmus MM, Verhaar R, Andringa G, Bol JG, Cras P, Shan L, et al. Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol. 2011;21:130-9.
159. Nath S, Goodwin J, Engelborghs Y, Pountney DL. Raised calcium promotes alpha-synuclein aggregate formation. Mol Cell Neurosci. 2011;46:516-26.
160. Izumi Y, Kume T, Akaike A. Regulation of dopaminergic neuronal death by endogenous dopamine and proteasome activity. Yakugaku Zasshi. 2011;131:21-7.
161. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 2008;115:409-15.
162. Sugeno N, Takeda A, Hasegawa T, Kobayashi M, Kikuchi A, Mori F, et al. Serine 129 phos-phorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem. 2008;283:23179-88.
163. Greffard S, Verny M, Bonnet AM, Beinis J Y, Gallinari C, Meaume S, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol. 2006;63:584-8.
164. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol. 2007;62:468-74.
165. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, et al. Differences in neuro-pathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67: 1931-4.
166. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci. 2010;1184:188-95.
167. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain. 2007;130:2123-8.
168. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007;25:134-49.
169. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55: 259-72.
170. Ishiyama M, Yagishita S, Hasegawa K, Yokoyama T. Ultrastructural study (tEM and sEM) of cortical Lewy bodies. Neuropathol. 2006;26:A58.
171. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, et al. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type his-topathology in human brains. Exp Neurol. 2013;240:190-204.
172. Ince PG, Clark B, Holton JL, Revesz T, Wharton SB. Disorders of movement and system degeneration. In: Love S, Louis DN, Ellison DW, editors. Greenfield's neuropathology. 8th ed. London: Hodder Arnold; 2008. p. 889-1030.
173. Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 2008;116:37-46.
174. Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, et al. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol. 2001;159:339-44.
175. Banerjee R, Starkov AA, Beal MF, Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta. 2009;1792:651-63.
176. Dugger BN, Dickson DW. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol. 2010;120:633-9.
177. Dugger BN, Murray ME, Boeve BF, Parisi JE, Benarroch EE, Ferman TJ, et al. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. Neuropathol Appl Neurobiol. 2012;38:142-52.
178. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, et al. Presence of striatal amyloid plaques in Parkinson's disease dementia predicts concomitant Alzheimer's disease: usefulness for amyloid imaging. J Parkinsons Dis. 2012;2:57-65.
179. Odagiri S, Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K. Autophagic adapter protein NBR1 is localized in Lewy bodies and glial cytoplasmic inclusions and is involved in aggregate formation in alpha-synucleinopathy. Acta Neuropathol. 2012;124:173-86.
180. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002;160:1655-67.
181. Sulzer D. Clues to how alpha-synuclein damages neurons in Parkinson's disease. Mov Disord. 2010;25 Suppl 1:S27-31.
182. Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, et al. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol. 2007;17:139-45.
183. Proteomic analysis of the substantia nigra in patients with Parkinson's disease. In: Abstracts of the movement disorder society's thirteenth international congress of Parkinson's disease and movement disorders. June 8-10, 2009. Mov Disord 2009; 24 Suppl 1: S39.
184. van Dijk KD, Berendse HW, Drukarch B, Fratantoni SA, Pham TV, Piersma SR, et al. The proteome of the locus ceruleus in Parkinson's disease: relevance to pathogenesis. Brain Pathol. 2012;22:485-98.
185. Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, et al. An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012;124:37-50.
186. Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:63-73.
187. Kanazawa T, Uchihara T, Takahashi A, Nakamura A, Orimo S, Mizusawa H. Three-layered structure shared between Lewy bodies and Lewy neurites-three-dimensional reconstruction of triple-labeled sections. Brain Pathol. 2008;18:415-22.
188. Ugrumov M V. Non-dopaminergic neurons partly expressing dopaminergic phenotype: distribution in the brain, development and functional significance. J Chem Neuroanat. 2009;38: 241-56.
189. Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord. 2011;26:6-17.
190. Hishikawa N, Hashizume Y, Yoshida M, Sobue G. Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease. Neuropathol Appl Neurobiol. 2001;27:362-72.
191. Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J Neuropathol Exp Neurol. 2004;63:329-37.
192. Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010;14:457-87.
193. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008;283: 9089-100.
194. Ferrer I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog Neurobiol. 2009;88:89-103.
195. Mullin S, Schapira A. Alpha-synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol. 2013;47:587-97.
196. Breydo L, Wu JW, Uversky VN. Alpha-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta. 1822;2012:261-85.
197. Stefanis L. Alpha-synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2:a009399.
198. Wan OW, Chung KK. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PLoS One. 2012;7:e38545.
199. Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, et al. Endoplasmic reticu-lum stress is important for the manifestations of alpha-synucleinopathy in vivo. J Neurosci. 2012;32:3306-20.
200. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA. 2011;108:4194-9.
201. Gadad BS, Britton GB, Rao KS. Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-beta peptide. J Alzheimers Dis. 2011;24 Suppl 2:223-32.
202. Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. Alpha-synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol. 2013;73:155-69.
203. Tashiro M, Kojima M, Kihara H, Kasai K, Kamiyoshihara T, Uéda K, et al. Characterization of fibrillation process of alpha-synuclein at the initial stage. Biochem Biophys Res Commun. 2008;369:910-4.
204. Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, et al. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol Commun. 2013;1:1. doi: 10.1186/2051-5960-1-6.
205. Yasuda T, Nakata Y, Mochizuki H. Alpha-synuclein and neuronal cell death. Mol Neurobiol. 2013;47:466-83.
206. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy. 2011;7:279-96.
207. Xilouri M, Brekk OR, Stefanis L. Alpha-synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol. 2013;47:537-51.
208. Fujita Y, Ohama E, Takatama M, Al-Sarraj S, Okamoto K. Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol (Berl). 2006;112:261-5.
209. Muller SK, Bender A, Laub C, Högen T, Schlaudraff F, Liss B, et al. Lewy body pathology is associated with mitochondrial DNA damage in Parkinson's disease. Neurobiol Aging. 2013;34:2231-3.
210. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord. 2006;21:2042-51.
211. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863-72.
212. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology. 2008;70:1042-8.
213. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318:121-34.
214. Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 2012;8:329-39.
215. Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm. 2011;118:821-39.
216. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol. 1988;7:299-305.
217. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord. 2010;25 Suppl 1:S78-82.
218. Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl. 2006;70:99-103.
219. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain. 2010;133: 1755-62.
220. Muller CM, de Vos RA, Maurage CA, Thal DR, Tolnay M, Braak H. Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter-and intra-rater reliability. J Neuropathol Exp Neurol. 2005;64:623-8.
221. Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta. 2009;1792:730-40.
222. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol. 2008;116:125-8. author reply 129-31.
223. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol. 2008;34:284-95.
224. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115:399-407.
225. Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 2008;18:220-4.
226. Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, Crain B, et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol. 2005;64: 156-62.
227. Marui W, Iseki E, Kato M, Akatsu H, Kosaka K. Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease. Acta Neuropathol. 2004;108:121-8.
228. Boeve BF, Dickson DW, Olson EJ, Shepard JW, Silber MH, Ferman TJ, et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 2007;8:60-4.
229. Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, Delledonne A, et al. Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 2011;32:857-63.
230. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75:494-9.
231. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol. 2011;69:811-8.
232. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm. 2004;111:1219-35.
233. Aho L, Parkkinen L, Pirttila T, Alafuzoff I. Systematic appraisal using immunohistochem-istry of brain pathology in aged and demented subjects. Dement Geriatr Cogn Disord. 2008; 25:423-32.
234. Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol. 2009;68:816-22.
235. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol. 2003;62:363-7.
236. Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol. 2004;63:742-9.
237. Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol. 2003;106:374-82.
238. Ding ZT, Wang Y, Jiang YP, Hashizume Y, Yoshida M, Mimuro M, et al. Characteristics of alpha-synucleinopathy in centenarians. Acta Neuropathol. 2006;111:450-8.
239. Fujishiro H, Tsuboi Y, Lin WL, Uchikado H, Dickson DW. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol. 2008;116:17-24.
240. Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I. Widespread and abundant alpha-synu-clein pathology in a neurologically unimpaired subject. Neuropathology. 2005;25:304-14.
241. Jellinger KA. Interaction between alpha-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218. Exp Neurol. 2011;227:13-8.
242. Kovacs GG, Botond G, Budka H. Protein coding of neurodegenerative dementias: the neu-ropathological basis of biomarker diagnostics. Acta Neuropathol. 2010;119:389-408.
243. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Res. 2001;888:287-96.
244. Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, et al. Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol (Berl). 2003;105:265-70.
245. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003;4:727-38.
246. Baum L, Seger R, Woodgett JR, Kawabata S, Maruyama K, Koyama M, et al. Overexpressed tau protein in cultured cells is phosphorylated without formation of PHF: implication of phosphoprotein phosphatase involvement. Brain Res Mol Brain Res. 1995;34:1-17.
247. Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, Tamura K, et al. Stimulatory effect of alpha-synuclein on the tau-phosphorylation by GSK-3beta. FEBS J. 2011; 278:4895-904.
248. Duka T, Duka V, Joyce JN, Sidhu A. Alpha-synuclein contributes to GSK-3beta-catalyzed tau phosphorylation in Parkinson's disease models. FASEB J. 2009;23:2820-30.
249. Kozikowski AP, Gaisina IN, Petukhov PA, Sridhar J, King LT, Blond S Y, et al. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. Chem Med Chem. 2006;1:256-66.
250. Kaul T, Credle J, Haggerty T, Oaks AW, Masliah E, Sidhu A. Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. BMC Neurosci. 2011;12:79.
251. Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, Sidhu A. Tauopathic changes in the stria-tum of A53T alpha-synuclein mutant mouse model of Parkinson's disease. PLoS One. 2011; 6:e17953.
252. Qureshi HY, Paudel HK. Parkinsonian neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote tau protein phosphory-lation at ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem. 2011;286: 5055-68.
253. Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. 2011;31:7604-18.
254. Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Gonçalves SA, Pera M, et al. Tau enhances a-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One. 2011;6:e26609. doi: 10.1371/journal.pone.0026609.
255. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300:636-40.
256. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI. Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol. 2010;42:1775-8.
257. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 2004;187:279-88.
258. Emmer KL, Waxman EA, Covy JP, Giasson BI. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent detrimental motor impairments. J Biol Chem. 2011;286:35104-18.
259. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. Alpha-Synuclein improves diagnostic and prognostic performance of tau and A-beta in Alzheimer's disease. Acta Neuropathol. 2013. doi:10.1007/s00401-013-1148-z.
260. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging. 2005;26:1183-92.
261. Huang HC, Jiang ZF. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis. 2009;16:15-27.
262. Lashley T, Holton JL, Gray E, Kirkham K, O'Sullivan SS, Hilbig A, et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 2008;115:417-25.
263. Bate C, Gentleman S, Williams A. Alpha-synuclein induced synapse damage is enhanced by amyloid-beta1-42. Mol Neurodegener. 2010;5:55.
264. Obi K, Akiyama H, Kondo H, Shimomura Y, Hasegawa M, Iwatsubo T, et al. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol. 2008;210:409-20.
265. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res. 2006;31:1153-62.
266. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Co-occurrence of Alzheimer's disease ss-amyloid and tau pathologies at synapses. Neurobiol Aging 2010; 31:1145-52.
267. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA. 2009;106:20057-62.
268. Obeso JA, Lanciego JL. Past, present, and future of the pathophysiological model of the Basal Ganglia. Front Neuroanat 2011;5:39.
269. Calabresi P, Mercuri NB, Di Filippo M. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Brain. 2009;132:285-7.
270. Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B. Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans. 2010;38:493-7.
271. Wu T, Hallett M. The cerebellum in Parkinson's disease. Brain. 2013;136:696-709.
272. Jellinger KA. Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl. 1999;56:1-29.
273. Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology. 2005; 64:545-7.
274. Lee FJ, Wang YT, Liu F. Direct receptor cross-talk can mediate the modulation of excitatory and inhibitory neurotransmission by dopamine. J Mol Neurosci. 2005;26:245-52.
275. West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci. 2002;22: 294-304.
276. Reetz K, Gaser C, Klein C, Hagenah J, Büchel C, Gottschalk S, et al. Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Mov Disord. 2009;24:99-103.
277. Mori F, Tanji K, Zhang H, Kakita A, Takahashi H, Wakabayashi K. Alpha-synuclein pathology in the neostriatum in Parkinson's disease. Acta Neuropathol. 2008;115:453-9.
278. Wichmann T, DeLong MR, Guridi J, Obeso JA. Milestones in research on the pathophysiol-ogy of Parkinson's disease. Mov Disord. 2011;26:1032-41.
279. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol. 2002;52:205-10.
280. Deutch AY, Colbran RJ, Winder DJ. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord. 2007;13 Suppl 3:S251-8.
281. Ito H, Kusaka H, Matsumoto S, Imai T. Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy. Neurology. 1996;47:1291-9.
282. Baradaran N, Tan SN, Liu A, Ashoori A, Palmer SJ, Wang ZJ, et al. Parkinson's disease rigidity: relation to brain connectivity and motor performance. Front Neurol. 2013;4:67.
283. Picconi B, Paille V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, et al. L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis. 2008; 29:327-35.
284. Ding Y, Won L, Britt JP, Lim SA, McGehee DS, Kang UJ. Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in Parkinsonian mice. Proc Natl Acad Sci USA. 2011;108:840-5.
285. Lee J, Zhu WM, Stanic D, Finkelstein DI, Horne MH, Henderson J, et al. Sprouting of dopa-mine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain. 2008;131:1574-87.
286. Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain. 2011;134: 979-86.
287. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskine-sias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9:1106-17.
288. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 1991;50:743-55.
289. Elias S, Israel Z, Bergman H. Physiology of Parkinson's disease. In: Hallett M, Poewe W, editors. Therapeutics of Parkinson's disease and other movement disorders. Chichester: Wiley-Blackwell; 2008. p. 25-36.
290. Benninger DH, Thees S, Kollias SS, Bassetti CL, Waldvogel D. Morphological differences in Parkinson's disease with and without rest tremor. J Neurol. 2009;256:256-63.
291. Ni Z, Pinto AD, Lang AE, Chen R. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol. 2010;68:816-24.
292. Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Toni I. Pallidal dysfunction drives a cere-bellothalamic circuit into Parkinson tremor. Ann Neurol. 2011;69:269-81.
293. Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR. Cerebral causes and consequences of Parkinsonian resting tremor: a tale of two circuits? Brain. 2012;135:3206-26.
294. Mure H, Hirano S, Tang CC, Isaias IU, Antonini A, Ma Y, et al. Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage. 2011;54:1244-53.
295. Volkmann J. Surgery Parkinson's disease. In: Hallett M, Poewe W, editors. Therapeutics of Parkinson's disease and other movement disorders. Oxford: Wiley-Blackwell; 2008. p. 120-43.
296. Desouza RM, Moro E, Lang AE, Schapira AH. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol. 2013;73:565-75.
297. Hallett M, Deuschl G. Are we making progress in the understanding of tremor in Parkinson's disease? Ann Neurol. 2010;68:780-1.
298. Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L. Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT SPECT. Basal Ganglia. 2011;1:34.
299. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010;9:1200-13.
300. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009;72:1121-6.
301. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75:1062-9.
302. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol. 2010;20:633-9.
303. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20: 190-9.
304. Kalaitzakis ME, Pearce RK. The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathol. 2009;118:587-98.
305. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain. 2011;134:1493-505.
306. Dickson D, Orr C, Murray M, Pahwa R, Lyons K, Goldman S, et al. Hierarchical cluster analysis of cortical pathology suggests pathologic heterogeneity of dementia in Parkinson's disease (abs). J Neuropathol Exp Neurol. 2011;70:505.
307. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66:1447-55.
308. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007;22:1272-7.
309. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007;130:1787-98.
310. Dalrymple-Alford JC, Livingston L, MacAskill MR, Graham C, Melzer TR, Porter RJ, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord. 2011;26: 629-36.
311. Adler CH, Caviness JN, Sabbagh MN, Shill HA, Connor DJ, Sue L, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010;120:827-8.
312. Jellinger KA. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010;120:829-30.
313. McKinlay A, Grace RC, Dalrymple-Alford JC, Roger D. Cognitive characteristics associated with mild cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord. 2009;28:121-9.
314. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63: 665-72.
315. Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis. 2010;19:221-8.
316. Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson's disease dementia. Brain Pathol. 2010;20:646-53.
317. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010; 74:77-84.
318. Evans JR, Revesz T, Barker RA. Lesions associated with cognitive impairment and dementia. In: Halliday G, Barker RA, Rowe DB, editors. Non-dopamine lesions in Parkinson's disease. Oxford: Oxford University Press; 2011. p. 261-87.
319. Bouchard TP, Malykhin N, Martin WR, Hanstock CC, Emery DJ, Fisher NJ, et al. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging. 2008;29:1027-39.
320. Fujita M, Ichise M, Zoghbi SS, Liow JS, Ghose S, Vines DC, et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol. 2006;59:174-7.
321. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008;70: 1470-7.
322. Jellinger KA. Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm Suppl. 1997;51:57-82.
323. Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry. 2013;84:774-83.
324. Zweig RM, Cardillo JE, Cohen M, Giere S, Hedreen JC. The locus ceruleus and dementia in Parkinson's disease. Neurology. 1993;43:986-91.
325. McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA, et al. Differential response of the central noradrenergic nervous system to the loss of locus coeru-leus neurons in Parkinson's disease and Alzheimer's disease. Brain Res. 2011;1373:240-52.
326. Aarsland D, Londos E, Ballard C. Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. Int Psychogeriatr. 2009;21:216-9.
327. Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology. 2005;64:2069-73.
328. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33:2091-105.
329. Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117:635-52.
330. Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, et al. Pathologic accumulation of alpha-synuclein and A-beta in Parkinson disease patients with dementia. Arch Neurol. 2012;69:1326-31.
331. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70: 223-8.
332. Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, Togo T, et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett. 2010;486:19-23.
333. Halliday GM, Song YJ, Harding AJ. Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm. 2011;118:713.
334. Piggott MA, Perry EK, Marshall EF, McKeith IG, Johnson M, Melrose HL, et al. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biol Psychiatry. 1998;44:765-74.
335. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord. 2007;22 Suppl 17:S351-7.
336. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 2000;54:1916-21.
337. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathol-ogy: later-developing dementia and loss of the levodopa response. Arch Neurol. 2002; 59:102-12.
338. Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (Berl). 2003;106:83-8.
339. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M. Alpha-Synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 2000;100:285-90.
340. Mattila PM, Rinne JO, Helenius H, Roytta M. Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol (Berl). 1999;98:157-64.
341. Harding AJ, Halliday GM. Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol. 1998;24:195-201.
342. Joelving FC, Billeskov R, Christensen JR, West M, Pakkenberg B. Hippocampal neuron and glial cell numbers in Parkinson's disease-a stereological study. Hippocampus. 2006; 16:826-33.
343. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74: 852-6.
344. Libow LS, Frisina PG, Haroutunian V, Perl DP, Purohit DP. Parkinson's disease dementia: a diminished role for the Lewy body. Parkinsonism Relat Disord. 2009;15:572-5.
345. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology. 2007;69: 356-9.
346. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008;115:127-36.
347. Jendroska K, Lees AJ, Poewe W, Daniel SE. Amyloid beta-peptide and the dementia of Parkinson's disease. Mov Disord. 1996;11:647-53.
348. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Mov Disord. 2003;18:81-6.
349. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331-8.
350. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71:903-10.
351. Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39:1027-33.
352. Ghebremedhin E, Rosenberger A, Rub U, Vuksic M, Berhe T, Bickeböller H, et al. Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. J Neuropathol Exp Neurol. 2010;69:442-8.
353. Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson's disease and alpha-synuclein expression. Mov Disord. 2011;26:2160-8.
354. Pilsl A, Winklhofer KF. Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol. 2012;123:173-88.
355. Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord. 2013;28:41-50.
356. Schapira AH, Gegg M. Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis. 2011;2011:159160.
357. Reynolds NP, Soragni A, Rabe M, Verdes D, Liverani E, Handschin S, et al. Mechanism of membrane interaction and disruption by alpha-synuclein. J Am Chem Soc. 2011;133: 19366-75.
358. Piccoli G, Condliffe SB, Bauer M, Giesert F, Boldt K, De Astis S, et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci. 2011; 31:2225-37.
359. Wang X, Winter D, AshrafiG, Schlehe J, Wong YL, Selkoe D, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011;147:893-906.
360. Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2:a009423.
361. Tzoulis C, Tran GT, Schwarzlmuller T, Specht K, Haugarvoll K, Balafkan N et al. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. Brain 2013;136:2393-404.
362. Hurley MJ, Brandon B, Gentleman SM, Dexter DT. Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain. 2013;136: 2077-97.
363. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegen-eration associated with Parkinson's disease. Brain. 2008;131:1969-78.
364. Janda E, Isidoro C, Carresi C, Mollace V. Defective autophagy in Parkinson's disease: role of oxidative stress. Mol Neurobiol. 2012;46:639-61.
365. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31: 3038-62.
366. Bueler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis. 2010;15:1336-53.
367. Schon EA, Przedborski S. Mitochondria: the next (neurode)generation. Neuron. 2011;70: 1033-53.
368. Coskun P, Wyrembak J, Schriner SE, Chen HW, Marciniack C, Laferla F, et al. A mitochon-drial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta. 2012;1820: 553-64.
369. Karbowski M, Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol. 2012;123:157-71.
370. McCoy MK, Cookson MR. Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid Redox Signal. 2012;16:869-82.
371. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011;26:1049-55.
372. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis. 2009;16:879-95.
373. Angot E, Steiner JA, Lema Tome CM, Ekström P, Mattsson B, Björklund A, et al. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One. 2012;7:e39465.
374. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegen-erative diseases. Nat Rev Mol Cell Biol. 2010;11:301-7.
375. Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, et al. Boosting chaperone-mediated autophagy in vivo mitigates alpha-synuclein-induced neurodegeneration. Brain. 2013;136:2130-46.
376. Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta. 2009;1792:643-50.
377. Huang Y, Chegini F, Chua G, Murphy K, Gai W, Halliday GM. Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T a-synuclein mutation. Translat Neurodeg. 2012;1:2. doi: 10.1186/2047-9158-1-2.
378. Visanji NP, Brooks PL, Hazrati L-N, Lang AE. The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun. 2013;1:2. doi: 10.1186/2051-5960-1-2.
379. Olanow CW, McNaught K. Parkinson's disease, proteins, and prions: milestones. Mov Disord. 2011;26:1056-71.
380. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42.
381. Marques O, Outeiro TF. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 2012;3:e350.
382. Fellner L, Jellinger KA, Wenning GK, Stefanova N. Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol. 2011;121:675-93.
383. Martin ZS, Neugebauer V, Dineley KT, Kayed R, Zhang W, Reese LC, et al. Alpha-synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem. 2012;120:440-52.
384. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015-25.
385. Bove J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience. 2012; 211:51-76.
386. Cannon JR, Greenamyre JT. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res. 2010;184:17-33.
387. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect. 2011;119:866-72.
388. Nistico R, Mehdawy B, Piccirilli S, Mercuri N. Paraquat-and rotenone-induced models of Parkinson's disease. Int J Immunopathol Pharmacol. 2011;24:313-22.
389. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron. 2010;66:646-61.
390. Welchko RM, Leveque XT, Dunbar GL. Genetic rat models of Parkinson's disease. Parkinsons Dis. 2012;2012:128356.
391. Alberio T, Lopiano L, Fasano M. Cellular models to investigate biochemical pathways in Parkinson's disease. FEBS J. 2012;279:1146-55.
392. Mizuno H, Fujikake N, Wada K, Nagai Y. Alpha-synuclein transgenic drosophila as a model of Parkinson's disease and related synucleinopathies. Parkinsons Dis. 2010;2011:212706.
393. Whitworth AJ. Drosophila models of Parkinson's disease. Adv Genet. 2011;73:1-50.
394. Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, et al. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol Dis. 2010;40:73-81.
395. Antony PM, Diederich NJ, Balling R. Parkinson's disease mouse models in translational research. Mamm Genome. 2011;22:401-19.
396. Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Mov Disord. 2011;26:993-1002.
397. Bezard E, Yue Z, Kirik D, Spillantini MG. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord. 2013;28:61-70. doi: 10.1002/mds.25108.
398. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol. 2012;2012:845618. doi: 10.1155/2012/845618.
399. Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol. 2011;10:1108-18.
400. Lim Y, Kehm VM, Lee EB, Soper JH, Li C, Trojanowski JQ, et al. alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci. 2011;31:10076-87.
401. Low K, Aebischer P. Use of viral vectors to create animal models for Parkinson's disease. Neurobiol Dis. 2012;48:189-201.
402. Ulusoy A, Bjorklund T, Buck K, Kirik D. Dysregulated dopamine storage increases the vulnerability to alpha-synuclein in nigral neurons. Neurobiol Dis. 2012;47:367-77.
403. Eschbach J, Danzer KM. α-Synuclein in Parkinson's Disease: Pathogenic Function and Translation into Animal Models. Neurodegener Dis 2014;14:1-17.
404. Blandini F, Armentero MT. Animal models of Parkinson's disease. FEBS J. 2012;279: 1156-66.